Eugene J. Teoh
University of Oxford
Bayesian probabilityCancerInternal medicineRadiologyPET-CTOncologyStage (cooking)ChemistryPositron emission tomographyChemotherapyBiochemical recurrenceNeoadjuvant therapyGlutamineEsophageal cancerReconstruction algorithmProstate cancerSalvage therapyRecurrent prostate cancerNuclear medicineFdg pet ctCancer researchBreast cancerImage qualityMedicine
Publications 32
#1Eric H. Kim (WashU: Washington University in St. Louis)H-Index: 16
#2Barry A. Siegel (WashU: Washington University in St. Louis)H-Index: 103
Last. Gerald L. Andriole (WashU: Washington University in St. Louis)H-Index: 97
view all 4 authors...
Abstract Introduction Despite improvements in overall survival, biochemical recurrence of prostate cancer, characterized by rising prostate-specific antigen (PSA) levels after curative intent primary therapy, remains common. With the advent of highly sensitive molecular imaging, men with limited metastatic disease burden, or oligometastatic prostate cancer, are increasingly being identified. The LOCATE trial (NCT02680041) assessed the impact of positron emission tomography (PET) with 18F-flucicl...
#1Abhishek A. Solanki (LUC: Loyola University Chicago)H-Index: 11
#2Bital Savir-Baruch (LUC: Loyola University Chicago)H-Index: 13
Last. Jian Q. YuH-Index: 27
view all 44 authors...
Purpose Conventional imaging rarely localizes the site(s) of prostate cancer recurrence in patients undergoing evaluation for salvage radiotherapy (sRT) after radical prostatectomy (RP). XXX (NCTXXX) was a prospective multicenter study investigating the impact of 18F-fluciclovine positron emission tomography/computed tomography (PET/CT) on the management of patients with biochemical recurrence of prostate cancer after curative-intent radiation or RP and negative or equivocal conventional imaging...
2 CitationsSource
#1Andrew Scarsbrook (Leeds Teaching Hospitals NHS Trust)H-Index: 29
#2David Bottomley (Leeds Teaching Hospitals NHS Trust)H-Index: 20
Last. Fergus V. Gleeson (University of Oxford)H-Index: 58
view all 18 authors...
Abstract Purpose Early and accurate localisation of lesions in patients with biochemical recurrence (BCR) of prostate cancer may guide salvage therapy decisions. The present study, XXX, aimed to evaluate the impact of 18F-fluciclovine on management of men with BCR of prostate cancer. Methods Men with a first episode of BCR following curative-intent primary therapy were enrolled at 6 UK sites. Patients underwent 18F-fluciclovine PET/CT according to standardised procedures. Clinicians documented m...
14 CitationsSource
#1So Won Oh (TUM: Technische Universität München)H-Index: 13
#2Alexander Wurzer (TUM: Technische Universität München)H-Index: 9
Last. Matthias Eiber (TUM: Technische Universität München)H-Index: 55
view all 11 authors...
Objectives: Radiohybrid PSMA (rhPSMA) ligands, a new class of theranostic PSMA-targeting agents, feature fast (18)F synthesis and utility for labelling with radiometals. Here, we assessed the biodistribution and image quality of (18)F-rhPSMA-7 to determine the best imaging time point for patients with prostate cancer (PCa). Methods: A total of 202 PCa patients who underwent a clinically indicated (18)F-rhPSMA-7 PET/CT were retrospectively analyzed, and 12 groups were created based on the adminis...
9 CitationsSource
#1Matteo Morotti (University of Oxford)H-Index: 19
#2Esther Bridges (University of Oxford)H-Index: 11
Last. Adrian L. Harris (University of Oxford)H-Index: 191
view all 19 authors...
Tumor hypoxia is associated with poor patient outcomes in estrogen receptor-α–positive (ERα + ) breast cancer. Hypoxia is known to affect tumor growth by reprogramming metabolism and regulating amino acid (AA) uptake. Here, we show that the glutamine transporter, SNAT2, is the AA transporter most frequently induced by hypoxia in breast cancer, and is regulated by hypoxia both in vitro and in vivo in xenografts. SNAT2 induction in MCF7 cells was also regulated by ERα, but it became predominantly ...
28 CitationsSource
#1Sohee OhH-Index: 18
Last. Hans-J. WesterH-Index: 4
view all 9 authors...
#1Simon Lord (University of Oxford)H-Index: 11
#2Wei Chen Cheng (University of Oxford)H-Index: 3
Last. Adrian L. Harris (University of Oxford)H-Index: 191
view all 31 authors...
Late-phase clinical trials investigating metformin as a cancer therapy are underway. However, there remains controversy as to the mode of action of metformin in tumors at clinical doses. We conducted a clinical study integrating measurement of markers of systemic metabolism, dynamic FDG-PET-CT, transcriptomics, and metabolomics at paired time points to profile the bioactivity of metformin in primary breast cancer. We show metformin reduces the levels of mitochondrial metabolites, activates multi...
39 CitationsSource
#1Funmilayo Tade (Emory University)H-Index: 7
Last. David M. Schuster (Emory University)H-Index: 33
view all 17 authors...
We investigated if previously demonstrated inhibition of fluciclovine (18F) in vitro could be replicated in a PC3-Luc xenograft mouse model. Following intratumoral injection of 2-aminobicyclo-(2,2,1)-heptane-2-carboxylic acid (BCH), alpha-(methylamino)isobutyric acid (MeAIB) or saline, fluciclovine PET tumor-to-background activity was 43.6 (± 5.4)% and 25.3 (± 5.2)% lower in BCH (n = 6) and MeAIB (n = 5) injected PC3 Luc xenografts, respectively, compared to saline-injected controls (n = 2). Par...
#1Eugene J. Teoh (University of Oxford)H-Index: 11
#2David Bottomley (Leeds Teaching Hospitals NHS Trust)H-Index: 20
Last. Fergus V. Gleeson (University of Oxford)H-Index: 58
view all 18 authors...
165Background: Detection of the extent of local recurrence and of metastases in biochemical recurrence (BCR) of prostate cancer facilitates selection of appropriate treatment. The FALCON trial (NCT02578940) assessed the impact of 18F-fluciclovine PET/CT on the clinical management of men with BCR of prostate cancer following initial radical therapy. Methods: Men being considered for curative-intent salvage therapy following first BCR were recruited at 6 UK sites. Management plans were documented ...
2 CitationsSource